The countries included in the agreement are South Africa, Namibia, Zimbabwe, Mozambique, Swaziland, Lesotho and Botswana. This is the tenth licensing agreement for Zepzelca®, with the objective of making this therapy accessible to patients worldwide.
PharmaMar (MSE:PHM) has announced today that it has signed a licensing agreement with Key Oncologics (Pty) Ltd., for the commercialization and distribution of Zepzelca® (lurbinectedin), its marine-derived anti-tumor compound for Small Cell Lung Cancer (SCLC), in South Africa, Namibia, Zimbabwe, Mozambique, Swaziland, Lesotho and Botswana.
PharmaMar will retain exclusive production rights, while Key Oncologics (Pty) Ltd will apply for marketing approval and will have the right to market the product on an exclusive basis. This expands the commercial relationship between the two companies, which in 2020 signed a commercial alliance for the sale and distribution of Yondelis® in South Africa, Namibia and Botswana.
This agreement brings to 10 the number of strategic alliances signed by PharmaMar with its partners around the world for the commercialization of lubinectedin. Luis Mora, General Manager of the Oncology, Virology and Genetic Identification Business Units, said: “This new agreement expands the possibilities for patients to access innovative medicines. As a global company, PharmaMar works through alliances with strategic partners to make our therapies available to doctors and patients”.
Magriet de Wet, CEO of Key Oncologics (Pty) Ltd said:
“We are very pleased to extend our partnership with PharmaMar. PharmaMar shares our values, and we are excited about the opportunity that Zepzelca® represents for Key Oncologics (Pty) Ltd. and for Small Cell Lung Cancer patients in South Africa, Namibia, Zimbabwe, Mozambique, Swaziland, Lesotho and Botswana. This milestone provides an exciting prospect to grow our portfolio further and strengthen our position as leaders in the Oncology market in the mentioned territories.
We look forward to many more years of a mutually beneficial association.”
Lurbinectedin is approved in 13 countries around the world for the treatment of adult patients with SCLC with disease progression during or after platinum-based chemotherapy. SCLC accounts for up to 15% of all lung cancer cases[1].
[1] Data Monitor: Small Cell Lung Cancer (SCLC) Globocan 2020. All ages, both genders.
English Español
